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ABSTRACT
Diffuse Large B-Cell Lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. Though histologically DLBCL
shows varying morphologies, no morphologic features have been consistently demonstrated to correlate with prognosis. We
present a morphologic analysis of histology sections from 209 DLBCL cases with associated clinical and cytogenetic data.
Duplicate tissue core sections were arranged in tissue microarrays (TMAs), and replicate sections were stained with H&E and
immunohistochemical stains for CD10, BCL6, MUM1, BCL2, and MYC. The TMAs are accompanied by pathologist-annotated
regions-of-interest (ROIs) that identify areas of tissue representative of DLBCL. We used a deep learning model to segment all
tumor nuclei in the ROIs, and computed several geometric features for each segmented nucleus. We fit a Cox proportional
hazards model to demonstrate the utility of these geometric features in predicting survival outcome, and found that it achieved
a C-index (95% CI) of 0.635 (0.574,0.691). Our finding suggests that geometric features computed from tumor nuclei are of
prognostic importance, and should be validated in prospective studies.
Background & Summary
Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), accounting for over a
third of cases1 with more than 20,000 patients diagnosed annually in the United States2. DLBCL is fatal without treatment,
however approximately 70% of patients can be cured with contemporary therapeutic regimens3. Treatment outcomes following
standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy are highly variable, and
depend on a number of clinical, biologic, and genetic factors. Currently, the most effective prognostic classification is the
National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI), which incorporates five clinical variables
including age, lactate dehydrogenase (LDH), extra-nodal sites of involvement, Ann Arbor stage, and ECOG performance
status4. The NCCN-IPI model is widely used to risk stratify patients into good, intermediate, and poor-risk categories, however
it is insufficient to guide therapeutic decision-making for individual patients.
Gene expression profiling (GEP) studies revealed distinct subtypes of DLBCL that correspond to differences in cell of
origin (COO) and show different outcomes in response to R-CHOP therapy5, 6. This approach categorizes DLBCL as either
germinal center B-cell (GCB), activated B-cell (ABC), or indeterminate, based on the phase of B-cell development it most
closely resembles7. A practical algorithm employing this approach for immunohistochemically stained, formalin fixed, paraffin
embedded tissue was developed by Hans et al, and despite imperfect concordance with the gold standard GEP method, it is
now the most widely used algorithm in the United States for DLBCL8. The GCB subtype is associated with more favorable
outcomes than the non-GCB subtype5, 9–13.
In addition to COO subtyping, double-hit lymphomas with concurrent chromosomal translocations of the MYC and BCL2
genes, or less commonly MYC and BCL6 genes, and double-expressor lymphomas with dual overexpression of MYC and
BCL2 proteins have been found to correlate with an aggressive clinical course and poor outcomes when treated with R-CHOP14.
Determination of these molecular subsets is now standard of care per the World Health Organization (WHO) guidelines and
patients harboring dual chromosomal translocations are now formally classified as having high grade B-cell lymphoma, with
ar
X
iv
:2
00
9.
08
12
3v
1 
 [c
s.C
V]
  1
7 S
ep
 20
20
Annotated core Extracted Patch Segmented Tumor Nuclei
Single Nucleus 
Segmentation Map
Neoplastic Nucleus 
Masks
Hull area
449 px
Min diameter
25 px
Max diameter
28 px
Elongation
1.12
...
Shape and Size 
Features
a. b. c.
e.d. f.
Figure 1. Data pipeline for a single core from an H&E stained tissue microarray (TMA). In a) the red rectangle is the
pathologist-annotated ROI. In c) red corresponds to cell nuclei classified as “neoplastic" by HoVer-Net. Green corresponds to
“inflammatory" and orange corresponds to “non-neoplastic epithelial".
MYC and BCL2 and/or BCL6 translocations (HGBL)15.
While COO subtyping by the Hans algorithm corresponds to morphologically distinct benign precursors, germinal center
type B-cells and activated B-cells, classification based on the morphologic properties of the tumor itself has historically been
challenging due to the significant histomorphologic heterogeneity of DLBCL. Cytologically, DLBCL may resemble centroblasts
with multiple peripheral nucleoli and vesicular chromatin or immunoblasts with abundant cytoplasm and a single prominent
nucleolus. However, the prognostic significance of these and other recognised cytologic variants, for example anaplastic type
DLBCL, is unclear and the subject of continued debate16–21.
Though several studies have thus far failed to conclusively demonstrate that morphologic classification can predict
outcomes in DLBCL, automated imaging methods could potentially identify novel, prognostically significant morphological
or immunohistochemical biomarkers. The ability of automated methods to identify prognostically relevant features on H&E
sections that have eluded pathologists has been demonstrated22–24. If successful, automated image analysis could be scaled up
into a cost-effective alternative to current classification methods which are typically costly and/or labor intensive. A critical
requirement for the development of these models is the availability of datasets containing digitally scanned slides stained to
show cell morphology and expression of relevant proteins with accompanying prognostic outcome data.
Here we present DLBCL-Morph, a publicly available dataset containing 42 digitally scanned high-resolution tissue
microarrays (TMAs) from 209 DLBCL cases at Stanford Hospital. Each TMA was stained for H&E as well as for CD10, BCL6,
MUM1, BCL2, and MYC protein expression. All of the TMAs are accompanied by pathologist-annotated regions-of-interest
(ROIs) that indicate areas representative of DLBCL. For each patient in the dataset, we provide survival data, follow-up status,
and a wide range of clinical and molecular variables such as age and MYC/BCL2/BCL6 gene translocations. We also segmented
out tumor nuclei from ROIs inside the H&E stained TMAs, and provide several geometric features for each tumor nucleus.
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Figure 2. Tissue microarrays (TMAs) with region-of-interest (ROI) annotations. a) H&E stained TMA. The red
rectangles denote ROIs annotated by a human expert. Some missing or unrepresentative cores have no ROIs. b) A single core
from the TMA in a) with ROI that ignores unrepresentative areas of the core. c) BCL6 stained TMA, containing cores from the
same patients as a). d) A single annotated core from the TMA in c). Cells stained orange show greater BCL6 expression.
Methods
Our dataset contains digitally scanned TMAs accompanied by pathologist-annotated ROIs. We extracted patches from the ROIs
inside the H&E stained TMAs, and used a deep learning model called HoVer-Net25 to segment tumor cell nuclei. We then
computed several geometric descriptors for each segmented nucleus. Figure 1 shows our pipeline for an H&E stained TMA
core. Our project was approved by the Institutional Review Board of Stanford University. All protected health information was
removed and the project had no impact on clinical care, so the requirement for individual patient consent was waived.
Patient Cohort
The study cohort consists of patients with de novo, CD20+ DLBCL treated with curative intent with R-CHOP or R-CHOP–like
immunochemotherapy with available clinical data from the Stanford Cancer Institute, Stanford, California. This patient cohort
was included in a prior study with clinicopathologic inclusion criteria are as previously described26.
Tissue Microarray
Stained tissue microarray (TMA) slides were scanned at 40x magnification (0.25 µm per pixel) on an Aperio AT2 scanner
(Leica Biosystems, Nussloch, Germany) in ScanScope Virtual Slide (SVS) format. This high magnification level displays the
tissue in very fine detail, which we believe to be beneficial for the development of automated imaging models. Each SVS file
also contains a slide label image, a macro camera image, and a thumbnail image. The slide label image is a low-resolution
image of the slide’s label, which shows the TMA number and the stain (eg: BCL2). The macro camera image is a low-resolution
picture of the entire slide. The thumbnail is an image of the whole scanned TMA.
Our dataset includes 7 TMAs, each with a 0.4 micron thick formalin-fixed, paraffin-embedded (FFPE) section of tumors
assembled in a grid. Within the microarray each tumor is represented by a 0.6-mm core diameter sample in duplicate. Replicates
of each TMA were stained with H&E, which shows cell morphology. They were also stained for the expression of the
following 5 oncogenes: CD10, BCL6, MUM1, BCL2, and MYC. We therefore have 6 stains per TMA, resulting in 42 distinct
digitally-scanned slides. An example of an H&E stained TMA is shown in Figure 2 a) and a BCL6 stained TMA is shown
in Figure 2 c). Since overexpression of one or more of these proteins is observed in a significant portion of DLBCL cases,
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Figure 3. Rectangle and ellipse fitted to a single segmented tumor nucleus. a) a binary segmentation image for a tumor
cell nucleus. For visual clarity, the image is zero-padded by 5 pixels on each side. b) rotated rectangle fit to the nucleus. Our
dataset provides the rectangle’s center coordinates, width, height and rotation angle. c) rotated ellipse fit to the nucleus. Our
dataset provides the ellipse’s center coordinates, perimeter, area, and major and minor axis lengths.
automated imaging models can use the immunostained TMAs to potentially identify prognostically significant features related
to protein expression.
Pathologist annotations
Although TMA cores were already taken from areas of tissue showing DLBCL, some of the cores were partially or entirely
missing. Furthermore, some cores still contained areas of tissue that had very few or no tumor cells. We obtained rectangular
ROI annotations from expert pathologists to highlight the core regions which represent DLBCL accurately. The annotations
were created for all TMAs and all stains at 40x magnification. The pixel coordinates for the rectangles in ROIs, along with the
corresponding deidentified unique patient_id, are included in our dataset. We believe the exclusion of missing or insufficiently
representative tissue areas will be beneficial for automated prognostic models which use patches from the TMAs as input.
Example ROI annotations are shown in Figure 2 b) and d).
Patches from stained TMAs
We extracted patches of size 224x224 from within the ROIs in the stained TMAs, at 40x magnification. The patches were
extracted uniformly from inside each annotated rectangle, starting from the top-left corner and proceeding until the bottom-right
corner. The patches are non-overlapping, and we omitted patches that are mostly white and contain little tissue. We provide
these patches as part of our dataset. Due to our ROI annotation process detailed above, our patches exclude missing and
unrepresentative areas of cores. Since deep learning based imaging methods typically cannot directly operate on images as
large as the 40x magnification image, the patches can instead be used as input. We also used patches from H&E stained TMAs
to segment tumor cell nuclei as described below.
Tumor cell nucleus segmentation
We used a deep learning based nucleus segmentation and classification model called HoVer-Net to segment every tumor cell
inside each of the patches from H&E stained TMAs. The HoVer-Net operates independently on each patch, and produces
an output image segmenting all individual cell nuclei in the patch, and another output image specifying the classification of
each segmented nucleus. The HoVer-Net classifies segmented nuclei into 5 categories: neoplastic, non-neoplastic epithelial,
inflammatory, connective, dead. HoVer-Net uses a neural network based on a pretrained ResNet-50 architecture to extract
image features. These extracted features are then processed in three steps: the nuclear pixel (NP) step, HoVer step, and nuclear
classification (NC) step. The NP step determines whether each pixel belongs to a nucleus or the background, and the HoVer
step predicts the vertical and horizontal distances of nucleus pixels to their centroid, thereby allowing separation of touching
nuclei. Then the NC step classifies each nucleus pixel, and aggregates these across all pixels in a segmented nucleus to classify
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each nucleus as neoplastic, non-neoplastic epithelial, inflammatory, connective, or dead. We used the HoVer-Net output to
identify each neoplastic cell nucleus in a patch, and saved it as a separate binary image, thereby obtaining one binary image
for each tumor cell. Each binary image illustrates the size and shape of the nucleus, and we provide these in our dataset. An
example binary image is shown in Figure 1 e) and another is shown in Figure 3 a). We used these binary images to compute
geometric features for each tumor cell nucleus as described below.
Geometric features from tumor nuclei
We used the per-nucleus binary segmentation images to compute several geometric features for each tumor cell nucleus. While
end-to-end imaging models may not require such hand-crafted features, prognostic models which use these features can give
more explainable results, and can more clearly indicate the prognostic importance of these features.
We fit a (possibly rotated) rectangle of minimum area enclosing the binary mask, and provide the rectangle’s top left point
coordinates, width and height, and rotation angle. An example rectangle is shown in Figure 3 b). The rectangle’s top left point
is a tuple corresponding to the feature rectCenter. The first element of the tuple corresponds to the x-coordinate, and the second
element corresponds to the y-coordinate. The width and height are in a tuple corresponding to the feature rectDimension. The
first element of the tuple corresponds to the width, and the second element to the height. The rotation angle corresponds to
the feature rotate_angle, which ranges from −90◦ to 0◦. A value of −90◦ corresponds to an axis-aligned rectangle. As the
rectangle is rotated clockwise, the angle increases toward 0◦, at which point the rectangle is again axis-aligned and the angle
resets to −90◦.
We fit an ellipse around the nucleus in the binary segmentation mask, and provide the ellipse center, major axis, minor axis,
perimeter and area of the ellipse. An example ellipse is shown in Figure 3 c). The ellip_centroid parameter is a tuple containing
the x and y coordinates of the ellipse. The features shortAxis and longAxis correspond to the lengths of the minor and major
axes respectively. The feature ellip_perimt corresponds to the ellipse perimeter, and ellip_area corresponds to the ellipse area.
We computed the maximum and minimum Feret diameters for each segmented nucleus, and provide the corresponding
angles. Given an object and a fixed direction, the Feret diameter is the distance between two parallel tangents to the object,
where the tangents are perpendicular to the fixed direction. The feature maxDiameter contains the Feret diameter maximized
over all directions, and maxAngle specifies the angle (between −180◦ and 180◦) at which the maximum diameter is obtained.
The features minDiameter and minAngle are similar but for the minimum Feret diameter. We further computed the convex hull
of the segmented nucleus. The feature hull_area corresponds to the area of the convex hull.
Finally we computed a number of geometric features derived from the quantities described above. These features are esf,
csf, sf1, sf2, elongation, and convexity. These are defined below in (1)− (6). The esf, sf1, sf2 and elongation are all simple
ratios that can be thought of as measures of how “elongated" the nucleus is. In particular, they are all equal to 1 if the nucleus is
perfectly circular. The csf is similar: it is a measure of circularity, and is equal to 1 if the nucleus is perfectly circular. For
increasingly elliptical nuclei, the csf decreases towards 0.
esf =
shortAxis
longAxis
(1)
csf =
4pi ∗ ellip_area
ellip_perimt2
(2)
sf1 =
shortAxis
maxDiameter
(3)
sf2 =
minDiameter
maxDiameter
(4)
elongation =
maxDiameter
minDiameter
(5)
convexity =
√
ellip_area
hull_area
(6)
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Data Records
The DLBCL-morph dataset is organized into three folders, TMA, Patches, and Cells as is shown by Figure 4. The clinical
data of the patients together with the outcome is stored in clinical_data.xlsx and clinical_data_cleaned.csv where the latter
contains all the patients for which the outcome is recorded and all categorical variables are converted to numerical values, e.g.
‘neg’, ‘pos’, and ‘no data’ were converted to 0, 1, and NaN, respectively for the variable CD10 IHC. Each patient has a unique
identifier. There are 209 patients recorded in clinical_data_cleaned.csv. The column OS records the overall survival which is
the length of time (in years) from the end of treatment until death or last follow-up. The column Follow-up Status (FUS) is 1 if
the patient was deceased at the time of last follow-up, else 0.
TMA
The TMA folder contains a total of 42 digitally-scanned TMAs, which are organized within subfolders for each stain. The
filename of each TMA is a TMA id which is the same across all stains, i.e. DLBCL-Morph/TMA/HE/TMA255 and DLBCL-
Morph/TMA/BCL2/TMA255 contains cores of the same set of patients. The TMA id together with the row and column number
of each core, starting with 0 and 0, respectively in the upper left corner, can be linked to the patient id through core.csv, each
patient has two cores. The annotations.csv contains coordinates of ROIs annotated by human experts. For each annotation there
is a patient id, TMA id, and stain where the TMA id and the stain is used to locate the TMA file that the annotation belongs to.
The annotations are rectangular and the coordinates record the upper left and lower right corners based on the 40x magnification
level of the TMAs.
Figure 4. The directory structure of DLBCL-Morph
Patches
The Patches folder contains subfolders of stains which contains subfolders of patients that has at least one ROI. The patches are
localized in the folders of patient ids with a patch id as the filename and are stored in PNG format. There are 195 patients that
have at least one patch from at least one stained TMA. However, some patients do not contain patches for all 6 stains, which
can occur if the core for a particular stain was missing or not covered by any ROIs.
Cells
The Cells folder contains subfolders of patient ids which contains subfolders of patch ids. The binary segmentation images
for tumor cell nucleus are localized in the folders of patch ids with the cell number as the filename and stored in NPY format.
The NPY format is used by the Numpy package for Python to save arrays, in this case we are storing 2-dimensional arrays
with binary values as segmentations of tumor cell nucleus. The cell numbers are non-consecutive since all non-tumor cells are
discarded in each patch. All the geometric features computed from tumor nuclei are stored in cell_shapes.csv and can be linked
to the nucleus segmentation images through the patch id and the cell number.
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Technical Validation
We performed survival regression using the geometric and clinical features in our dataset to measure the utility of these features
in predicting prognostic outcome. This analysis was performed on the 170 patients for whom patches from H&E stained TMAs
were available. For each of the geometric features computed per tumor nucleus, we computed the mean and standard deviation
across all nuclei for each patient. We then fit Cox Proportional Hazards models using the binary Follow-up Status (FUS) feature
as an indicator of censoring, and the overall survival (OS) feature as the time to event or censoring (in years). We evaluated our
models using Harrel’s C-index27. Random prediction would give a C-index of 0.5. Specifically we fit three models: i) using
both clinical and geometric features ii) using only clinical features iii) using only geometric features.
We used the bootstrap method to obtain an “optimism-corrected" C-index28. We sampled 1000 bootstrap replicates with
replacement and fit the model on each bootstrap replicate. We then evaluated the model on both the original data and the
bootstrap replicate. We recorded the performance decrease between evaluating on the bootstrap replicate and evaluating on
the original data. This decrease, averaged over all bootstrap replicates, was subtracted from the original C-index to obtain
the optimism-corrected C-index. We also generated the corresponding 95% two-sided confidence intervals (CI) for the
optimism-corrected C-indices using the non-parametric percentile bootstrap method29 with 1000 bootstrap replicates.
The resulting optimism-corrected C-indices with 95% CIs for our models were: i) 0.700 (0.651,0.744) using clinical and
geometric features, ii) 0.674 (0.602,0.737) using only clinical features and iii) 0.635 (0.574,0.691) using only geometric
features. Thus, use of the geometric features alone allowed significantly better than random survival prediction. Use of both
clinical and geometric features led to a higher performance than the use of clinical features alone, although this performance
difference was not statistically significant. While prognostic classification based on the morphologic properties of the tumor has
proved to be challenging and the subject of continued debate,16–21 our results suggest that geometric features computed from
H&E-stained tumor nuclei can provide a significant signal to predict surival outcome. This finding should be further evaluated
on external datasets and prospectively in future studies.
Usage Notes
The DLBCL-Morph dataset is available for download here: https://figshare.com/s/ec3481685a15e377cc36. The data is
organized as shown in Figure 4. We have provided publicly available Jupyter Notebooks30, 31 to illustrate computation of
geometrical features as well as usage of the data. One notebook uses the clinical and geometric variables in the dataset to
reproduce the survival regression results described in the Technical Validation section. Another notebook visualizes and
reproduces the computation of several geometric features for any segmented tumor nucleus in our dataset. Finally, we
provide another notebook to extract patches uniformly from inside any of the ROIs in the dataset. These patches are already
included as part of the dataset, but we believe this notebook will be beneficial for researchers who work with the SVS files
in our dataset. The notebooks, along with the code to compute all geometrical features from tumor nuclei, are provided at
https://github.com/stanfordmlgroup/DLBCL-Morph.
Code availability
The code to compute all geometric features from all tumor nuclei in our dataset, along with notebooks to illustrate usage of our
data and reproduce all survival regression results, is publicly available at https://github.com/stanfordmlgroup/DLBCL-Morph.
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